Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus Therapeutics (NASDAQ:AUTL) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Autolus Therapeutics (NASDAQ:AUTL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Autolus Therapeutics (AUTL) Valuation Check After Revenue Guidance And AUCATZYL UK And EU Approvals [Yahoo! Finance]
Autolus Therapeutics (NASDAQ:AUTL) had its price target lowered by analysts at Needham & Company LLC from $11.00 to $10.00. They now have a "buy" rating on the stock.